OLR1 is an immune-related prognostic biomarker with potential as a prognostic indicator for immunotherapy, and it may also be involved in regulating the EMT process and cuproptosis in HNSCC. This evidence concerns the gene OLR1 and head and neck squamous cell carcinoma.